Advertisement
Document › Details
Memo Therapeutics AG. (6/11/18). "Press Release: Memo Therapeutics AG Announced that Dr. Karsten Fischer Was Appointed as Chief Executive Officer of the Company Effective June 01, 2018". Basel.
Organisation | Memo Therapeutics AG (MTx) | |
Organisation 2 | BioMedPartners AG | |
Group | BioMedPartners (Group) | |
Product | MemoMAB™ antibody discovery platform | |
Product 2 | venture capital | |
Person | Fischer, Karsten (Memo Therapeutics 201806–202311 CEO before BioMedPartners + WestLB LEFT 11/23) | |
Person 2 | Burckhardt, Peter E. (Basel Inkubator 201603 CEO) | |
Memo Therapeutics AG announces that Dr. Karsten Fischer was appointed as Chief Executive Officer of the company effective June 01, 2018.
Dr. Fischer will lead the company as its orientation shifts from technological excellence towards pharma partnerships and product development. Founder and former interim CEO, Dr. Christoph Esslinger will focus his efforts as Chief Scientific Officer on the continued advancement of the MemoMAB platform and on the expansion of MEMO’s proprietary antibody discovery programs in immune-oncology and infectious diseases.
Prior to joining MEMO, Dr. Fischer was a partner of BioMedPartners AG and invested in several successful companies in the life science field. Before that, Dr. Fischer has been working for WestLB on equity, M&A, and debt transactions in the healthcare and chemicals sector. Moreover, he has a track record in management consulting with McKinsey and pharmaceutical sales&marketing with Sanofi. He holds a Ph.D. in infection biology (MPI Infection Biology and Colorado State University, with distinction).
“Memo is poised to establish its MemoMAB technology as a world leading platform for antibody discovery and has developed a highly promising pipeline. I am very much looking forward to help the company to manage the next evolutionary step and on bringing its strong value proposition into partnerships and its own pipeline” said Karsten Fischer.
Dr. Peter Burckhardt, Chairman of the Memo Supervisory Board, commented: “As we look to the next phase of growth for Memo, we are very pleased to have been able to recruit Karsten to develop the company to become a major player in the field of therapeutic antibody discovery and development.”
Record changed: 2023-06-05 |
Advertisement
More documents for Memo Therapeutics AG (MTx)
- [1] Memo Therapeutics AG. (11/16/23). "Press Release: Memo Therapeutics AG Appoints Erik van den Berg as Chief Executive Officer". Schlieren....
- [2] Memo Therapeutics AG. (11/02/23). "Press Release: Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Development of AntiBKV for BKV Infection in Renal Transplant Patients". Schlieren....
- [3] Memo Therapeutics AG. (6/22/23). "Press Release: Memo Therapeutics AG Starts U.S. Pivotal Phase II/III Clinical Trial with AntiBKV for Treatment of BKV Infection in Renal Transplant Patients". Schlieren....
- [4] Memo Therapeutics AG. (5/2/23). "Press Release: Memo Therapeutics AG Receives FDA Fast Track Designation for AntiBKV as Treatment of BKV Infection in Renal Transplant Patients". Schlieren....
- [5] Memo Therapeutics AG. (1/24/23). "Press Release: Memo Therapeutics AG Announces Positive Phase I Data with AntiBKV for Treatment of BKV Infection in Renal Transplant Patients". Schlieren....
- [6] Memo Therapeutics AG. (11/1/22). "Press Release: Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets". Schlieren....
- [7] Verve Capital Partners AG (Verve Ventures). (6/24/22). "Press Release: Verve Ventures Launches Investment Fund to Support Portfolio Companies"....
- [8] Memo Therapeutics AG. (2/26/22). "Press Release: Memo Therapeutics AG Closes Series B Financing at CHF37 Million Following Oversubscribed CHF23 Million Extension". Schlieren....
- [9] Memo Therapeutics AG. (12/13/21). "Press Release: Memo Therapeutics AG to Receive CHF 10.5 Million from Swiss Federal Funding Programme to Clinically Develop SARS-CoV-2 Antibody Against COVID-19". Schlieren....
- [10] Memo Therapeutics AG. (7/6/21). "Press Release: Memo Therapeutics AG Appoints Seasoned Executives Elias Papatheodorou as Chairman and Dr. Thomas Taapken as Member to Board of Directors". Schlieren....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top